D. Boral Capital restated their buy rating on shares of Medicus Pharma (NASDAQ:MDCX - Free Report) in a research note published on Monday,Benzinga reports. D. Boral Capital currently has a $14.00 price objective on the stock.
A number of other analysts have also recently commented on MDCX. D Boral Capital raised Medicus Pharma to a "strong-buy" rating in a research report on Monday, April 14th. Brookline Capital Management raised Medicus Pharma to a "strong-buy" rating in a research note on Monday, December 23rd.
Check Out Our Latest Stock Analysis on Medicus Pharma
Medicus Pharma Stock Performance
Shares of NASDAQ:MDCX traded down $0.01 during trading on Monday, hitting $3.95. The stock had a trading volume of 81,510 shares, compared to its average volume of 51,653. The company has a fifty day moving average of $3.58. Medicus Pharma has a 12 month low of $1.80 and a 12 month high of $6.00.
Medicus Pharma (NASDAQ:MDCX - Get Free Report) last posted its quarterly earnings data on Friday, March 28th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.32) by $0.14. On average, equities analysts forecast that Medicus Pharma will post -1.14 EPS for the current fiscal year.
Institutional Trading of Medicus Pharma
A hedge fund recently bought a new stake in Medicus Pharma stock. Interchange Capital Partners LLC acquired a new stake in shares of Medicus Pharma Ltd. (NASDAQ:MDCX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 1,457,165 shares of the company's stock, valued at approximately $3,628,000. Medicus Pharma comprises about 1.3% of Interchange Capital Partners LLC's holdings, making the stock its 15th largest holding. Interchange Capital Partners LLC owned approximately 13.43% of Medicus Pharma at the end of the most recent reporting period.
Medicus Pharma Company Profile
(
Get Free Report)
Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.
Read More
Before you consider Medicus Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medicus Pharma wasn't on the list.
While Medicus Pharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
